TLR Reporter Cell Assay
Overview
A TLR reporter cell assay asks a narrow question cleanly: does this ligand engage this receptor? A cell line that does not normally respond to the ligand — canonically HEK293, which expresses few endogenous TLRs — is stably transfected with a single human TLR plus a transcriptional reporter, usually NF-κB-driven luciferase. The parent line carrying only the reporter serves as the control. If the ligand drives the reporter in the TLR-transfected line but not the parent, the receptor is sufficient for the response.
The design’s strength is attribution: a single receptor is added to an otherwise unresponsive background, so a positive result is receptor-specific in a way that inhibitor and knockdown experiments in primary cells are not. Its weakness is the mirror image, and it is the reason this page exists rather than being folded into a general in vitro page — see Limitations.
Key Points from Literature
- The canonical implementation: HEK293 stably transfected with human TLR7 and an NF-κB luciferase construct (HEK/hTLR7/NF-κB), against the parent HEK293/NF-κB line as control; maintained in DMEM + 10% FCS by continuous passage. Cells seeded at 5 × 10⁴/well in flat-bottom 96-well plates, stimulated in serum-free Opti-MEM, harvested at 40 h; luciferase read from lysates with a Dual-Glo system while the same wells’ supernatants were assayed by ELISA for IL-8, IFN-α and IFN-β (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro).
- Reading two signalling arms from one assay. Pairing an NF-κB luciferase readout with cytokine ELISA on the same supernatant separates TLR7→NF-κB→IL-8 from TLR7→type I IFN, which is how the source established that the two arms have different activation thresholds (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling).
- RNA ligands require transfection, not just addition. Genomic and synthetic RNAs were complexed with cationic lipid (Lipofectamine) for 20–30 min before addition, and concentrations were expressed as moles of RNA segments rather than mass — necessary when comparing an 11-kb dengue genome against a 21-nt siRNA, since equal mass is wildly unequal molarity (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling).
- Dynamic range across ligand classes is large. In one such assay, genomic viral RNAs signalled at 0.02–2 nM while siRNA 9.2 and ssRNA40 produced nothing at all across 0.02–2000 nM — a 10⁵-fold concentration range tested to establish a negative (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling).
- Reporting convention to check. Reporter-line figures are frequently published as “one representative experiment of four” rather than pooled replicates (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, Fig 5) — the pattern is reproduced, but no error bars across experiments are shown, so effect sizes read off such a figure are illustrative.
Contradictions & Debates
★ A negative in a reporter line is not a negative for the ligand. This is the method’s central trap and it is documented inside the source that uses it. R-848 and poly(U) drove NF-κB and IL-8 but produced no type I IFN in HEK/hTLR7 — yet primary Plasmacytoid Dendritic Cells made 13,694–18,381 pg/ml IFN-α to the same agonist. The authors attribute the difference to the reporter line’s low abundance of limiting downstream components, naming IRF-7. The general principle: a reporter line reports the branches it is equipped to run. Which downstream arm a ligand reaches is a joint property of ligand and cell, and an engineered line is by construction an impoverished cell. Any claim of the form “agonist X does not engage pathway Y” that rests only on a reporter line is unsafe (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling).
Sufficiency is not necessity. The design shows that a receptor is sufficient to transduce a ligand in a permissive background. It does not show the receptor is the route used in a primary cell that also expresses cytosolic sensors, other TLRs, and Fc receptors. Pairing the reporter line with an inhibitor or knockout experiment in the primary cell of interest — as the source does with IRS 661 in pDCs — is what closes that gap.
Related Pages
TLR7, TLR9, Plasmacytoid Dendritic Cell, Type I Interferon, Toll-like Receptor Signaling in B Cells, ELISA, In Vitro B Cell Stimulation